Escalon Medical Corp. Reports 4.4% Revenue Growth but Faces $142,175 Net Loss for Six Months Ending December 31, 2025

Escalon Medical Corp. reported its financial results for the six months ending December 31, 2025, revealing a net revenue increase of approximately $265,000, or 4.4%, totaling $6.27 million compared to $6.00 million in the same period last year. The growth was primarily driven by a $455,000 increase in sales of Sonomed products, although this was partially offset by a $207,000 decline in Trek product sales. For the three months ending December 31, 2025, net revenue rose by $370,000, or 11.5%, to $3.59 million, again attributed to Sonomed's performance.

Despite the revenue growth, the company reported a net loss of $142,175 for the six months ended December 31, 2025, compared to a net income of $213,804 for the same period in 2024. The loss was influenced by increased costs, with total costs and expenses rising to $6.37 million, up from $5.77 million in the prior year. The cost of revenue as a percentage of total revenue increased to 57.3%, reflecting a shift in product mix. Marketing, general, and administrative expenses also saw a rise of 7.7%, totaling $2.43 million, driven by higher payroll and advertising costs.

Operationally, Escalon Medical's cash position decreased to $337,434 as of December 31, 2025, down from $545,835 at the end of June 2025. The company fully repaid its outstanding TD Bank loan of $113,960 in October 2025, which contributed to a reduction in current liabilities. However, the current ratio declined to 1.65 from 1.72, indicating tighter liquidity. The company also reported an accumulated deficit of approximately $68.6 million, raising concerns about its ability to continue as a going concern.

In terms of strategic developments, Escalon Medical entered into a loan agreement in November 2025 with the Richard DePiano Sr. Trust, securing $100,000 to support working capital needs. Additionally, the company announced a significant asset sale to Optos Public Limited Company, which is expected to generate $3 million, with the first installment of $1 million received in January 2026. This transaction is anticipated to positively impact future financial results, although it will not be reflected in the current financial statements.

Looking ahead, Escalon Medical is actively pursuing partnerships and cost-cutting measures to improve its financial stability. The company acknowledges the challenges posed by market conditions, including tariffs and supply chain disruptions, which could affect profitability and operational efficiency. Management remains focused on enhancing product offerings and exploring new market opportunities to drive growth and improve financial performance in the coming quarters.